Photoablation increases refractive index of stroma

Article

Photoablation increases the refractive index of the stroma following laser in situ keratomileusis (LASIK) surgery, according to a study published in the July 2008 issue of the Journal of Cataract and Refractive Surgery.

Photoablation increases the refractive index of the stroma following laser in situ keratomileusis (LASIK) surgery, according to a study published in the July 2008 issue of the Journal of Cataract and Refractive Surgery.

Sudi Patel, PhD of Practitioner Services, CSA, NHS Scotland, Edinburgh, UK and colleagues performed LASIK in 49 subjects (76 eyes) using either a microkeratome (M2; Moria) or a femtosecond laser (IntraLase; AMO). Patients undergoing surgery with a microkeratome (57 eyes) had a mean pre-surgical refractive index of 1.366±0.0049 SD; those treated with the femtosecond laser (19 eyes), 1.374±0.0047. After lifting the flap, the team measured the refractive index of the stroma before and immediately after photoablation.

Postoperatively, the mean refractive index of the microkeratome group was 1.382±0.0066; in the femtosecond group, it was 1.391±0.0102. Following ablation, both groups demonstrated a statistically significant increase in refractive index. A longer treatment time was associated with a greater increase in the refractive index.

Thus the researchers concluded that photoablation increases the refractive index of the stroma and that there exists a linear correlation between treatment time and the magnitude of refractive index improvement.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.